Data for equity in transplant access and outcomes

Angela Webster

angela.webster@sydney.edu.au







Tēnā koutou, tēnā koutou, tēnā koutou katoa

Collaborative
Centre for
Organ
Donation
Evidence




Outline of talk - lots of NZ data

- Equity and dis/advantage
- Data integration as an art
- Aotearoa data to shape service design and delivery
- Bias in health care Australia
 - Data to challenge what we think we know









Lifestyle Cultural beliefs

Socioeconomic status

Race and ethnicity

Psychological factors

Age

Mobility and geographical factors

Education

Gender/Sex

Migration

Family support

Physiology and comorbidities

Familial and genetic factors

Care
Disparities



Intersection
Interaction

Multiple jeopardy

Its never one issue, it's "stackable" dis/advantage

SYSTEM RELATED

Monitoring and reporting

Reimbursement

Spatial barriers

Treatment delays

Survivorship

Screening programs

Clinical trial access

Equipment

Optimal treatment

Staff quality


Palliative and supportive care

Multidisciplinary working

Evidence-based medicine



Integrating data to reveal and address disparity in care





Integrating data to reveal and address disparity in care

- Caution in an era of "Big Data"
- Spectrum from simple linkage to very complex integration
- Applied methods






Integrating data to reveal and address disparity in care

Centre for Organ • Donation Evidence

- Caution in an era of "Big Data"
- Spectrum from simple linkage to very complex integration

Applied methods

EXPECTATION



- 42945 ASSET ANZDATACalciphylaxis
- 42945 ASSET ANZDATACancerInDonor
- 42945 ASSET ANZDATACancerNonSkinTumours
- 42945 ASSET ANZDATACancerSkinTumours
- 42945 ASSET ANZDATACentreHistory
- ## 42945 ASSET ANZDATACentreTransfers
- # 42945 ASSET ANZDATAComorbidities
- 42945 ASSET ANZDATAComorbiditiesOther
- 42945 ASSET ANZDATACourseOfTreatments
- 42945 ASSET ANZDATADialysis
- 42945 ASSET ANZDATAPatients
- ## 42945 ASSET ANZDATATransplant
- 42945 ASSET ANZDATATransplantCYADrug
- 42945 ASSET ANZDATATransplantRejectionEpisodes
- 42945 ASSET ANZDATATransplantRejectionTreatments
- ## 42945 ASSET ANZDATATransplantSerumCreatinine
- ## 42945 ASSET ANZDATATransplantTherapies
- 42945 ASSET ANZDATATransplantWeight
- 42945 ASSET LKDPatients
- BloodService_data
- MoH_cas2161
- MoH_dim_form_pack_subsidy
- MoH_ESKD_nhis
- MoH_LKD_nhis
- MoH_mos4089
- MoH_phh1030
- MoH_pus11131

- **図** cas2161
- dim_form_pack_subsidy
- ESKD_nhis
- LKD_nhis
- mos4089
- nap1022_2006_2007
- nap1022_2007_2008
- nap1022_2008_2009
- nap1022_2009_2010
- nap1022_2010_2011
- nap1022_2011_2012
- nap1022_2012_2013
- nap1022_2013_2014
- nap1022_2014_2015
- nap1022_2015_2016
- nap1022_2016_2017
- nap1022_2017_2018
- nap1022_2018_2019
- nap1022_2019_2020
- nap1022_2020_2021
- **≱** phh1030
- pus11131
- as2161

Integrating data needs care

- Starting point always has to be patient-centric
 - Better service design or delivery
- Design phase of study critical to meet the "So what?" test
 - Regularly re-visiting the nub of the rationale
- Mixed methodology as a starting point
 - Patient and clinician perspectives
 - Behaviour change



Integrating data can transform care

- Starting point always has to be patient-centric
 - Better service design or delivery
- Design phase of study critical to meet the "So what?" test
 - Regularly re-visiting the nub of the rationale
- Mixed methodology as a starting point
- This is the precision medicine of health services research





Lifestyle

Cultural beliefs

Socioeconomic status

Race and ethnicity

Psychological factors

Age

Mobility and geographical factors

Education

Gender/Sex

Migration

Family support

Physiology and comorbidities

Familial and genetic factors

Care
Disparities

Intersection
Interaction

Multiple jeopardy

Its never one issue, it's "stackable" dis/advantage



SYSTEM RELATED

Monitoring and reporting

Reimbursement

Spatial barriers

Treatment delays

Survivorship

Screening programs

Clinical trial access

Equipment

Optimal treatment

Staff quality

Palliative and supportive care

Multidisciplinary working

Evidence-based medicine





Lifestyle

Cultural beliefs

Socioeconomic status

Race and ethnicity

Psychological factors

Age

Mobility and geographical factors

Education

Gender/Sex

Migration

Family support

Physiology and comorbidities

Familial and genetic factors

Care
Disparities

Intersection
Interaction
Multiple jeopardy

Its never one issue, it's "stackable" dis/advantage



SYSTEM RELATED

Monitoring and reporting

Reimbursement

Spatial barriers

Treatment delays

Survivorship

Screening programs

Clinical trial access

Equipment

Optimal treatment

Staff quality

Palliative and supportive care

Multidisciplinary working

Evidence-based medicine





Lifestyle Cultural beliefs

Socioeconomic status

Race and ethnicity

Psychological factors

Age

Mobility and geographical factors

Education

Gender Sex

Migration

Family support

Physiology and comorbidities

Familial and genetic factors

Care
Disparities

Intersection
Interaction
Multiple jeopardy

Its never one issue, it's "stackable" dis/advantage



SYSTEM RELATED

Monitoring and reporting

Reimbursement Spatial barriers

Treatment delays

Survivorship

Screening programs

Clinical trial access

Equipment

Optimal treatment

Staff quality

Palliative and supportive care


Multidisciplinary working

Evidence-based medicine



Conceptualising equity of access


- Access to the waiting list
- Equity while waiting
- Achieving transplantation, post transplant outcomes
- When does waiting time to start? (CKD, dialysis initiation, or listing?)





What is the real lived experience of waiting?

- Individuals may cycle on- and off-waitlist (once or several times)
 - competing health events
- Individual experience on kidney waitlist not described
 - No initiatives to ensure fair waiting immortal time bias







HE RAWA RARAUNGA HAUORA MŌ NGĀ TĀNGATA O AOTEAROA

Projects People ▼ Publications and Output Opportunities

Related Links

Contact Us

ASSET has brought together data for New Zealanders with kidney disease, to investigate equity in access to best health outcomes, initially with a focus on kidney transplantation. These data include health and administrative data, which is anonymised.

Study cohort

ASSET linked data platform

ANZDATA

NZ Blood Service




Dialysis & kidney transplant





Ever waitlisted or in work-up for living kidney transplant



Deterministic linkage

Ministry of Health data



Hospital admissions & outpatient

National Non-Admitted Patient Collection Data National Minimum Dataset Cancer Registry



ANZLKD



Mental health



Programme for the integration of mental health data (PRIMHD)

Death Register



Prescription medications




Pharmaceutical Claims Database



ANZSN Key Performance Indicator: transplanted or "active" on the wait list within 6 months of ESKD

- Understanding the distribution of people with ESKD in Aotearoa will help service planning
- Health services might need adaptation or intensifying to meet need






Geographic variations in the epidemiology of kidney failure in New Zealand, 2006-2019


- Johanna Birrell
- ASSET's 1st research degree student



















*NZDep index of 9-10







Transplant units

Complexity of service provision



'Transplanting regions' District Health Boards with transplant unit, or adjacent




'Intermediate regions' = DHBs with nephrologists or visiting transplant staff.



'Remote regions' require referral to another DHB for nephrology review, followed by a second referral to a transplant unit.








KPI: Waitlisting / live donor transplant in 6 months of ESKD

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral






ASSET KIDNEY RESEARCH


Characterising mental illness in kidney failure

Kidney failure



n = 6,392 2008-2019

- Prasad Ravi
- ASSET's 1st nephrology trainee research affiliate



Mental illness

n = 1,631
(26%)

Mental illness in kidney failure

Prescription medication use




n = 803 (49%)

Antipsychotic: 130 (8%)

Antidepressant: 673 (41%)




Mental illness



n = 1,631



BOIH: 403 (25%)



Mental health services



n = 1,231 (76%)

Inpatient 97 (6%)

Community 1,134 (70%)

Mental illness in kidney failure

- Treated mental illness more common in younger people & females
- Less common in Maori, Pasifika,
 Asians

MODERATE

1432 (88%)

Mental illness




n = 1,631

SEVERE
199 (12%)

SEVERITY

Impact of mental illness on transplant KPIs

Mental illness BEFORE kidney failure



Adjusted for sociodemographic covariates, and comorbidities including BMI & smoking status.

Data integration has shown


- 1. Burden of kidney failure highly variable across Aotearoa
- 2. Service design associated poorer access to transplantation
- 3. People of Māori or Pacific ethnicity independently disadvantaged in waitlisting and live donor transplantation
- 4. 1 in 4 people with kidney failure in Aotearoa has moderate-severe mental illness, and this impacts their access to transplantation






Nicole De La Mata








KIDNEY RESEARCH

HE RAWA RARAUNGA HAUORA MÕ NGĀ TĀNGATA O AOTEAROA

Time per suspension

- ●30% were <3 months
- •34% were 3-12 months
- ●35% were >12 months



Made with SankeyMATIC

KIDNEY RESEARCH

HE RAWA RARAUNGA HAUORA MÕ NGĀ TĀNGATA O AOTEAROA

Transplant: 582 (38%)


Remained waiting: 98 (6%)

Remained suspended: 178 (12%)

Permanently suspended: 156 (10%)

Died: 527 (34%)

Equity in waitlist journey: staying on the waitlist




KIDNEY RESEARCH

HE RAWA RARAUNGA HAUORA MÕ NGĀ TĀNGATA O AOTEAROA

Made with SankeyMATIC

Equity in waitlist journey: staying on the waitlist



KIDNEY RESEARCH


HE RAWA RARAUNGA HAUORA MŌ NGĀ TĀNGATA O AOTEARO

Made with SankeyMATIC

38

Equity in waitlist journey: staying on the waitlist

Transplant: 582



KIDNEY RESEARCH

HE RAWA RARAUNGA HAUORA MÕ NGĀ TĀNGATA O AOTEAROA

Median time to transplant

- Never suspended = 1.0 year (IQR: 5 months to 1.9 years)
- Suspended at least once = 3.3 years (IQR: 1.8 to 4.8 years)

hsplant:

nained ting: 270

Remained

suspended: 178


Permanently

suspended: 156

Died: 570

Remained waiting: 172

Died: 43




QUICKLY JUMPING TO AUSTRALIAN DATA TO SHOW VALUE OF EXAMINING INTERSECTIONAL/STACKABLE DISADVANTAGE

Collaborative
Centre for
Organ
Donation
Evidence

What about equity considerations?

Unadjusted







Comparing transitions between sexes



Waitlist to off-waitlist

Off-waitlist to waitlist

Female


Male

Adjusted

age, calendar year, ethnicity, blood group, previous delisting episodes, comorbidity count, cause of kidney failure

Female

Male






Hazard ratio for transition





Off-waitlist to waitlist: intersectional disadvantage







Organ •

Donation

Evidence

Comparing endpoints between sexes

Unadjusted

Female

Male

Waitlist to transplant Waitlist to death before (deceased donor) transplant ** ** 0.6 8.0 1.0 1.2 1.4 1.6 0.6 8.0 1.0 1.2 1.6 1.4 Less likely More likely More likely Less likely

Hazard ratio





Comparing endpoints between sexes

Unadjusted

Female


Male

Adjusted

age, calendar year, ethnicity, blood group, previous delisting episodes, comorbidity count, cause of kidney failure

Female

Male







Centre for Organ • Donation Evidence

Kidney waiting list outcomes

This tool calculates expected outcomes after being waitlisted for a kidney transplant, based on patient characteristics Based on: De La Mata et al., 2023







Dashboard design in process to aid clinicianpatient discussions personalising likely journey

Outline of talk - lots of NZ data



• Equity and dis/advantage



• Data integration as an art




Aotearoa data to shape service design and delivery

- Bias in health care Australia
 - Data to challenge what we think we know



Data integration to shape approach to closing the gap



PUBLICATIONS

Eleanor Garrard and Stephen McDonald

Improving Access to and Outcomes of Kidney Transplantation for Aboriginal and Torres Strait Islander People in Australia: Performance Report National Indigenous Kidney Transplantation Taskforce

Performance Report: June 2022

Read \longrightarrow

Read ----

RCH

Reporting of Aboriginality in ANZDATA has not been validated




ANZDATA Reporting of Aboriginality

Australian and New Zealand Dialysis and Transplant Registry (ANZDATA)



Ever waitlisted for kidney transplant





Codes based on Australian Standard
Classification of Cultural and Ethnic Groups
(2016) by Australia Bureau of Statistics (ABS)











ANZDATA Reporting of Aboriginality pre 2014

```
10 Caucasoid
1101 Oceanian - Australian
1102 Oceanian - Australian Aboriginal
1103 Oceanian - Australian South Sea Islander
1104 Oceanian - Torres Strait Islander
1201 Oceanian - New Zealand Māori
1202 Oceanian - New Zealand European
1300 Oceanian - Melanesian And Papuan (Specify)
1400 Oceanian - Micronesian (Specify)
1500 Oceanian - Polynesian (Specify)
1501 Cook Islander
1502 Fijian
1503 Niuean
1504 Samoan
1505 Tongan
1508 Tokelauan
1515 Cook Islands Māori
2000 North-West European (Specify)
```

```
3000 Southern and Eastern European (Specify)
3103 Southern and Eastern European - Italian
3205 Southern and Eastern European - Greek
4000 North African and Middle Eastern (Specify)
4100 North African and Middle Eastern - Arab (Specify)
4907 North African and Middle Eastern - Turkish
5000 South-East Asian (Specify)
5107 South-East Asian - Vietnamese
5201 South-East Asian - Filipino
5202 South-East Asian - Indonesian
5205 South East Asian - Malay
6000 North - East Asian (Specify)
6101 North - East Asian - Chinese
7000 Southern and Central Asian (Specify)
7100 Southern Asian (Specify)
7106 Southern and Central Asian - Indian
7200 Central Asian (Specify)
8100 North American (Specify)
8105 Hispanic North American
8200 South American (Specify)
8300 Central American (Specify)
8400 Caribbean Islander (Specify)
9000 Sub-Saharan African (Specify)
9999 Other (Specify)
                                                       → for
```

Organ •

Donation

Evidence



Data sources: ASSET NSW collaboration


Australian and New Zealand Dialysis and Transplant Registry (ANZDATA)




Ever waitlisted for kidney transplant



Dialysis & kidney transplant



Mental Health Living Longer (MHHL)



Death Register


Cancer Registry



Cancer screening

Pap test register

Breast Screen NSW



Non-admitted

NSW Ambulance
















Enhanced Reporting of Aboriginality (ERA) method


 NSW Health data collections use the national standard indigenous question

 ERA algorithm routinely applied by NSW health to improve reporting of Aboriginality





Simple validation of ANZDATA Aboriginality



RCH





ANZDATA significantly underestimates Indigenous Australians

- 713 people identified as Aboriginal (6.1% of 11,708)
- •ANZDATA: 484 (67.9%) of 713
 - 229 people identified as Aboriginal in NSW health datasets, but not in ANZDATA
- MHLL (ERA): 693 (97.2%)
 - 20 people ANZDATA identified as Aboriginal that NSW health did not



ANZDATA significantly underestimates Indigenous Australians

- 713 people identified as Aboriginal (6.1% of 11,708)
- •ANZDATA: 484 (67.9%) of 713
 - 229 people identified as Aboriginal in NSW health datasets, but not in ANZDATA
- MHLL (ERA): 693 (97.2%)
 - 20 people ANZDATA identified as Aboriginal that NSW health did not

Missing were more likely younger, male, more affluent, live in urban area, have less comorbidity

Outcomes better for Indigenous Australians unrecognized by ANZDATA

Outcome %	ANZDATA &	ERA only	P
	ERA 464	229	
Waitlisted	17.5	25.3	0.02
Transplanted	11.9	23.1	< 0.001
Death	56.5	44.5	0.01



Outcomes better for Indigenous Australians unrecognized by ANZDATA

Outcome %	ANZDATA &	ERA only	P
	ERA 464	229	
Waitlisted	17.5	25.3	0.02
Transplanted	11.9	23.1	< 0.001
Death	56.5	44.5	0.01

Data governance critical if we are serious about acting on inequity. We need metrics and we need to maximise value in linkage to elevate our analyses



Why asking this question is important

The collection of every patient's Indigenous status is necessary for the government and other services to:

- plan and deliver appropriate health services for all Australians
- measure the impact of services on particular groups
- monitor trends and changes in the health and wellbeing of Australians over time.

The most accurate and reliable way to collect Indigenous status is to have patients answer the standard question for themselves.

It is also important to ask because Aboriginal and Torres Strait Islander patients may wish to see an Aboriginal Health Worker, or access specific Medicare services such as a Health Check.




When to ask the question

The Indigenous status question should be asked at the point of intake, when a patient's other details, such as name, date of birth, and address are being collected.

How to ask the question

This question should be asked of all patients irrespective of appearance, country of birth, or whether you personally know the patient or their family background:



'Are you [is the person] of **Aboriginal or Torres Strait** Islander origin?'

Patients may be asked the question in person or over the phone, or asked to complete a form.

It is important that the question is asked exactly as it is worded. Changing the question even slightly has the potential to alter the question's meaning, and this may in turn influence the patient's response.

How to record the answer

Patients should be provided with at least three response options:

- → No
- Yes, Aboriginal
- Yes, Torres Strait Islander




Islander origin, both 'Yes' boxes should be marked.


Alternatively, you may include a fourth response category:

Yes, both Aboriginal and Torres Strait Islander

When a patient is unable to answer

There are some situations when the patient will be unable to answer the question. In these instances it is acceptable for someone else—a close friend, relative or member of the household—to answer on the patient's behalf. You should verify this response with the patient at a later time if possible.





(Adaption of work by Interaction Institute for Social Change | Artist: Angus Maguire)



HE RAWA RARAUNGA HAUORA MÕ NGĀ TĀNGATA O AOTEAROA

New Zealand Investigators

Dr Nicholas Cross, Te Waipounamu/Waitaha (Canterbury), Te Whatu Ora

Dr Heather Dunckley, New Zealand Blood Service

Dr Ben Beaglehole, University of Otago

Dr Ian Dittmer, Te Toka Tumai (Auckland), Te Whatu Ora

Dr John Irvine, Te Waipounamu/Waitaha (Canterbury),

Te Whatu Ora

John Kearns

Dr Curtis Walker, Te Pae Hauora o Ruahine o Tararua (MidCentral), Te Whatu Ora

Merryn Jones, Kidney Health New Zealand

Sydney School of Public Health, University of Sydney

Dr Nicole De La Mata Prof Angela Webster A/Prof Patrick Kelly Prof Kate Wyburn Collaborative
Centre for
Organ
Donation

Evidence



Acknowledgements

Funding

Health Delivery Research Activation Grant 2020, Health Research Council of New Zealand Ross Bailey Nephrology Trust Fund 2020









Questions?























